Skye Bioscience Gets Nasdaq Notice Over Negative Stockholders' Equity

What happened

Skye Bioscience, Inc. (Nasdaq: SKYE), a San Diego-based pharmaceutical company, disclosed in a Form 8-K filed with the SEC on Aug. 19, 2026 that it received a written notification from the Listing Qualifications Department of The Nasdaq Stock Market LLC dated Aug. 18, 2026.

The notice states that, based on the company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, Skye's stockholders' equity was negative $497,307. Nasdaq Capital Market Listing Rule 5550(b)(1) requires a minimum of $2,500,000 in stockholders' equity. Skye therefore is not in compliance with that standard.

The filing states the notice has no immediate effect on the listing or trading of Skye's common stock, which continues to trade under the symbol "SKYE" on the Nasdaq Capital Market.

Skye's common stock closed at $2.23 on Aug. 19, 2026, up 18.62% from the prior close of $1.88, according to the price data provided. The sources provided do not establish what caused that price move. The filing does not state a reason for the timing or size of the stock's trading activity, and the company's statement on the Nasdaq notice does not attribute any cause to it.

The compliance process

Under Nasdaq Marketplace Rule 5810(c)(2)(C), the company has 45 calendar days from the notice — until Oct. 2, 2026 — to submit a specific plan to regain compliance with all Nasdaq Capital Market listing requirements, including its timeframe to complete that plan.

If Nasdaq accepts the plan, the filing states Nasdaq can grant an extension of up to 180 calendar days from the date of the notice, or until Feb. 14, 2027, for the company to evidence compliance. If the plan is not accepted, Skye has the right to appeal, and the common stock would remain listed on the Nasdaq Capital Market until the appeal process is complete.

To regain compliance, Skye must have stockholders' equity of at least $2,500,000, per the filing.

The filing states Skye "is currently evaluating various alternative courses of action to regain compliance," and that there can be no assurance the company will be able to regain compliance with the minimum stockholders' equity requirement or maintain compliance with other listing requirements. The filing does not identify which specific courses of action are under consideration.

The pending Redx Pharma transaction

The same 8-K includes disclosure about a proposed acquisition of Redx Pharma Limited by Skye Bioscience. The filing references a Transaction Agreement dated as of Aug. 14, 2026, by and between the company and Redx.

The filing states Skye intends to file a proxy statement with the SEC in connection with the transaction, and that the definitive version will be sent or provided to stockholders. Skye's securities to be issued in the proposed transaction are anticipated to be issued in reliance on an exemption from registration under Section 3(a)(10) of the Securities Act of 1933.

The filing also lists, among the risks and uncertainties it describes, "whether the Company will be successful in maintaining the listing of its common stock on Nasdaq and the effects of a reverse stock split." The filing does not state that a reverse stock split has been decided or approved. The sources provided do not establish any link between the Nasdaq notice and the Redx transaction beyond their disclosure in the same filing.

What this means

A Form 8-K is a "current report." Public companies file one to disclose material events that occur between their regular quarterly and annual reports, rather than waiting for the next scheduled report. The item number tells readers what kind of event it is. Item 3.01 specifically covers a notice of delisting or a failure to satisfy a continued listing rule or standard, or a transfer of listing. This filing was made under Item 3.01, and the obligation it satisfies is the company's duty to tell the market promptly that it has received such a notice.

Stockholders' equity is the accounting difference between what a company owns (its assets) and what it owes (its liabilities) — the residual value attributable to shareholders. When liabilities exceed assets, that figure is negative, as it is here at negative $497,307. Skye's liabilities exceeded its assets by roughly half a million dollars as of June 30, 2026.

Nasdaq's $2,500,000 minimum equity standard is one of several alternative continued-listing requirements for the Nasdaq Capital Market. Companies that fall below it can sometimes satisfy a different standard instead, but this filing only addresses Rule 5550(b)(1) and the equity shortfall. The size of the gap here is unusual: Skye is about $3.0 million below the threshold, because its equity is below zero.

A delisting notice of this type is not itself a delisting. Nothing changes on the exchange the day the notice arrives. The 45-day window is a deadline for submitting a written plan, not for fixing the balance sheet. The subsequent 180-day period, if granted, is the window for demonstrating compliance. If Nasdaq were to reject the plan and any appeal were to fail, the common stock would be subject to removal from the Nasdaq listing — the same Form 25 process through which any security is removed from an exchange. That is a later stage and has not happened here.

Skye Bioscience is a clinical-stage pharmaceutical company, which is to say it develops drug candidates and, like many companies at that stage, has not yet generated meaningful product revenue. Such companies typically fund operations by raising capital rather than from sales, and capital raises that add cash without immediately adding equity — or accumulating losses that reduce equity — can push stockholders' equity below a listing standard even while the company continues to operate. The filing does not attribute the negative equity to any specific cause or transaction.

The company has not stated how it will cure the shortfall. What the filing does establish is the deadline: Oct. 2, 2026 to submit a plan, and, if accepted, up to Feb. 14, 2027 to demonstrate compliance.